| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-138-2-200301210-00010 |
| P698 | PubMed publication ID | 12529091 |
| P50 | author | Marcello Tonelli | Q28360280 |
| P2093 | author name string | Gary Curhan | |
| Frank M Sacks | |||
| Bryce Kiberd | |||
| Cholesterol and Recurrent Events (CARE) Trial Investigators | |||
| Lemuel Moyé | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| P304 | page(s) | 98-104 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency | |
| P478 | volume | 138 |
| Q27005638 | A novel therapeutic effect of statins on nephrogenic diabetes insipidus |
| Q36179961 | Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model. |
| Q36547312 | Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists |
| Q49136022 | Approach to cardiovascular disease prevention in patients with chronic kidney disease |
| Q59926638 | Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction |
| Q35030586 | Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis |
| Q43010667 | Beneficial effects of statins on the kidney |
| Q34187551 | Benefits of statin therapy and compliance in high risk cardiovascular patients |
| Q36426077 | CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches |
| Q37106407 | Cardiovascular implications of chronic kidney disease in older adults |
| Q43168819 | Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial |
| Q37557361 | Cardiovascular risk factors in patients with chronic kidney disease |
| Q34631631 | Chronic kidney disease |
| Q37509290 | Chronic kidney disease and statins: improving cardiovascular outcomes. |
| Q58492145 | Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm S |
| Q79668908 | Chronic kidney disease: common, harmful and treatable--World Kidney Day 2007 |
| Q36739442 | Chronic kidney disease: common, harmful and treatable--World Kidney Day 2007. |
| Q35686515 | Chronic renal insufficiency and cardiovascular events in the elderly: findings from the Cardiovascular Health Study |
| Q38020764 | Clinical assessment and management of dyslipidemia in patients with chronic kidney disease |
| Q42119273 | Combined renin-angiotensin-aldosterone system blockade and statin therapy effectively reduces the risk of cerebrovascular accident in autosomal dominant polycystic kidney disease: a nationwide population-based cohort study |
| Q36551356 | Comorbid Heart Failure and Renal Impairment: Epidemiology and Management |
| Q34980772 | Consensus statement on management of dyslipidemia in Indian subjects |
| Q36288839 | Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation |
| Q36943996 | Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease |
| Q99610068 | Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry |
| Q33589563 | Disorders of lipid metabolism and chronic kidney disease in the elderly |
| Q35020237 | Dyslipidemia associated with chronic kidney disease |
| Q37864579 | Dyslipidemia in children with CKD: should we treat with statins? |
| Q35014627 | Dyslipidemia in chronic kidney disease: managing a high-risk combination |
| Q44483019 | Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial |
| Q33578185 | Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study |
| Q33588706 | Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials |
| Q58730413 | Effects of Statin Use in Advanced Chronic Kidney Disease Patients |
| Q37316017 | Eligibility for Statin Treatment in Korean Subjects with Reduced Renal Function: An Observational Study |
| Q35602657 | Emerging drugs for renal failure |
| Q30651756 | Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010. |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q35856902 | Evidence-based treatment of lipids in the elderly |
| Q38072029 | Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review |
| Q81461160 | Facts and ideas from anywhere |
| Q33416406 | Genetic polymorphisms and the risk of accelerated renal function decline in women |
| Q24194514 | HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis |
| Q24241472 | HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis |
| Q37151458 | Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes |
| Q45750535 | Impact of Statin Therapy on Renal Function and Long-Term Prognosis in Acute Coronary Syndrome Patients With Chronic Kidney Disease |
| Q33479788 | Increased mortality among survivors of myocardial infarction with kidney dysfunction: the contribution of gaps in the use of guideline-based therapies |
| Q89441468 | Incremental prognostic value of SPECT-MPI in chronic kidney disease: A reclassification analysis |
| Q33566655 | Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial |
| Q58362346 | Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 |
| Q46261519 | Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: the Austrian Hospital Screening Project (HSP) |
| Q38082646 | Management of cardiovascular disease in patients with kidney disease |
| Q89741990 | Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology |
| Q37239030 | Management of ischemic heart disease in patients with chronic kidney disease. |
| Q80857642 | Managing dyslipidemia in chronic kidney disease |
| Q36362775 | Managing the failing allograft |
| Q88031022 | Mesoporous Pravastatin Solid Dispersion Granules Incorporable Into Orally Disintegrating Tablets |
| Q51824398 | Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease. |
| Q28074264 | Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins |
| Q37741787 | New pharmacological treatments for improving renal outcomes in diabetes |
| Q37014196 | Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review |
| Q61187896 | Papel de las estatinas en la enfermedad renal crónica (ERC) |
| Q35826445 | Peripheral blood-derived endothelial progenitor cell therapy prevented deterioration of chronic kidney disease in rats. |
| Q26829812 | Pharmacologic management of chronic reno-cardiac syndrome |
| Q89903377 | Pharmacological interventions for heart failure in people with chronic kidney disease |
| Q35856929 | Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT. |
| Q57684751 | Progression of alterations in lipid metabolism in kidney transplant recipients over 5 years of follow-up |
| Q37335055 | Reducing lipids for CV protection in CKD patients-current evidence |
| Q58405284 | Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription |
| Q35792795 | Runx2 Expression in Smooth Muscle Cells Is Required for Arterial Medial Calcification in Mice |
| Q43025051 | Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid |
| Q38372669 | Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge |
| Q53412231 | Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD) study: Protocol and baseline characteristics of a randomized controlled trial. |
| Q37103758 | Slowing chronic kidney disease progression: results of prospective clinical trials in adults |
| Q46616086 | Statin therapy in patients with diastolic heart failure. |
| Q28554193 | Statins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis Risk |
| Q36232369 | Statins and proteinuria |
| Q36216422 | Statins in nephrotic syndrome: a new weapon against tissue injury |
| Q37986355 | Statins in the management of dyslipidemia associated with chronic kidney disease |
| Q37883015 | Statins, inflammation and kidney disease |
| Q35153302 | Stroke in chronic kidney disease: prevention and management |
| Q35675305 | Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation |
| Q45137324 | The interest of statins in nephrology |
| Q27007027 | Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. |
| Q37195404 | Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins |
| Q37517937 | Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease |
| Q46073252 | Urinary NGAL-Positive Acute Kidney Injury and Poor Long-term Outcomes in Hospitalized Patients |
| Q34052928 | Validating a case definition for chronic kidney disease using administrative data |
| Q46001964 | [Treating dyslipaemia in renal patients: evidences and implications]. |
Search more.